VivaZome’s Head of Regulatory and Clinical, Ms. Xenia Sango, is an invited speaker at the 5th Conference of the Australia and New Zealand Society for Extracellular Vesicles (ANZSEV) to be held in Gold Coast, Queensland on 9-11 November 2022. Xenia’s will present “Regulatory Affairs Relating to EV-based Therapeutics”. In addition, VivaZome’s CEO, Dr. David Haylock, and Ms. Sango will be part of an Expert Panel Discussion on “How to go Commercial”. Further, Dr Haylock and VivaZome Senior Scientist, Dr Smriti Krishna, are co-authors of the poster “Bioengineering exosomes to enhance brain targeting in a mouse traumatic brain injury model” by Dr. Min Chen and colleagues from the University of Queensland. Read more at: VivaZome Press Release 3 November 2022
VivaZome Therapeutics Pty Ltd has entered into a Memorandum of Understanding (MoU) with The University of Queensland (UQ) focussing on improved therapies for Traumatic Brain Injury (TBI) and post-traumatic epileptogenesis (PTE). TBI afflicts close to 69 million people globally. Under the MoU, VivaZome will collaborate with Professor David Reutens – Director of the Centre for Advanced Imaging (CAI) at UQ – and his colleagues to investigate exosomes for the treatment of TBI and PTE.
Click here to read more
VivaZome Therapeutics has been awarded the top prize in the 2022 Cytiva BioChallenge for the Australia and NewZealand region. The prize, valued at approximately AUD $200,000, will further assist VivaZome in its quest to develop off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the inaugural challenge for the ANZ region received 32 applications from various universities and companies. See more here
VivaZome Therapeutics Pty Ltd is delighted to be collaborating with researchers at the Australian National University (ANU) and other expert groups focussing on improved therapies for age-related macular degeneration (AMD). The project entitled “The use of extracellular vesicles (EVs) for therapeutic RNA delivery as a novel treatment for retinal degenerations” is supported by a grant from ANU under its Research Support Program 2022, and includes researchers from the ANU School of Medicine and Psychology, VivaZome, Canberra Health Services, Sydney University, Save Sight Institute, La Trobe University and Flinders University. See more here
ReNerve and VivaZome have entered a collaboration to combine their leading scaffold and exosome technologies, skills and experience to explore new solutions for the repair of spinal cord injuries. The two companies will work together to explore the potential of combining the ReNerve NervAlign® nerve cuff with VivaZome’s proprietary exosomes to enhance nerve regrowth in damaged spinal cords. The NervAlign® nerve cuff has potential to facilitate localised delivery of regenerative factors to damaged nerves whilst protecting the healing process, while the VivaZome exosomes have potential to stimulate the regeneration of functional neural tissue and reduce inflammation. Read more at http://vivazome.com/wp-admin/post.php?post=3028&action=edit
Viva Zome CEO David Haylock is presenting at the Annual Conference of the American Society of Gene and Cell Therapy on 13 May 2021 in an Industrial Symposium sponsored by Pall Corporation. His presentation is entitled “Exosome manufacture in a fixed-bed bioreactor, and overcoming production challenges” Read more at http://vivazome.com/wp-content/uploads/2021/05/VivaZome-ASGCT-release-11-May-2021.pdf
VivaZome Therapeutics Pty Ltd and La Trobe University today announced that they have entered into a new collaborative research project focussed on developing novel exosome therapeutics. Under the collaborative arrangement, VivaZome scientists will work alongside members of Professor Andrew Hill’s laboratory in the La Trobe Institute for Molecular Science (LIMS). Professor Hill is one of the world’s pre-eminent exosome researchers, and a member of the La Trobe Research Centre for Extracellular Vesicles, with its extensive suite of specialised technology and high-level expertise.
Click to read full media release. http://vivazome.com/wp-content/uploads/2021/02/VivaZome-La-Trobe-Uni-release-16-Feb-2021.pdf
BIA’s unique CIM (Convective Interaction Media) monolith chromatography technology will be used to purify exosomes from VivaZome’s cell cultures, with the aim of developing a high-efficiency downstream purification and concentration process for exosome production.
Click to read full media release. http://vivazome.com/wp-content/uploads/2021/01/VivaZome-BIA-release-21-Dec-2020.pdf
VivaZome features in lead article in International BioPharmaceutical Industry journal. “Exosome Therapeutics: Academic Curiosity or Commercial Reality” written by VivaZome CEO David Haylock and key academic collaborator Prof Andy Hill (La Trobe Uni).
Click here to read article: 2020-IBI_Summer-Vivazome
VivaZome’s David Haylock says his company’s decision to base themselves in the Research & Innovation Precinct at La Trobe University revolved largely around one key researcher. Read the full story here